Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NWK5clVPS3m2b4TvfIlkKEG|c3H5 NF;ve40yOCCwTR?= MnvzO|IhcA>? M{W3T2ROW09? NFvKdlZRd3SnboTpZZRmeyClYX3weI91cGWlaX6tbY5lfWOnZDDjfZRwfG:6aXPpeJk> M3P5ZVI1QTByOEez
HT-29 NWLXV21QS3m2b4TvfIlkKEG|c3H5 NV\vZpA2OTBibl2= MlnBO|IhcA>? M2n0SmROW09? MoniVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 MWmyOFkxODh5Mx?=
HT-29 Mn3VR5l1d3SxeHnjJGF{e2G7 Mk\INVAhdk1? NHLyZlY4OiCq MWDEUXNQ MYDQc5RmdnSrYYTld{A2NW[udX;yc5Vz[WOrbD3pcoR2[2WmIHP5eI91d3irY3n0fS=> NYjyVZBpOjR7MEC4O|M>
PC3 M4G5TGtqdmG|ZTDBd5NigQ>? NX3DdVRlOTByIH7N MmTiNUBp M2X3cGROW09? NG\2WWFRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> M3zSeFIyQTd6Nkiz
PC3 NXnEXVV4U2mwYYPlJGF{e2G7 MV:xNFAhdk1? NYjQSlBoOSCq MU\EUXNQ MljpSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MYmyNVk4QDZ6Mx?=
PC3 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OxTlEvPSEQvF2= NELpcpAyKGh? M3X6OmROW09? M16xcWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= NEnFPGMzOTl5OE[4Ny=>
HEK293 NX\SeGdrTnWwY4Tpc44hSXO|YYm= MV2xNFAhdk1? NF3YSXY5KGh? M3ro[2ROW09? NFi3VmJKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= Mof2NlE2Ozl|MEG=
BT-20 M{XIOWtqdmG|ZTDBd5NigQ>? NHvjbHEzOCEQvF2= MX7EUXNQ M13yTWRw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:w NGPJ[lkzOTN3M{W1NS=>
U937 MVfBcpRq[mGldHXybYFtKEG|c3H5 NIHTcHU2OCEQvF2= MUG0PEBp NGLxV25FVVOR NVzRSYJbUW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzz NHH4bpUzOTF2MkGwOi=>
U937 M1XCTmFvfGmkYXP0[ZJq[WxiQYPzZZk> NWP4e|c4PTBizszN M2rMXFQ5KGh? NEnG[FFFVVOR MnTGSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? MknHNlEyPDJzME[=
U937 MXXBcpRq[mGldHXybYFtKEG|c3H5 NVrZcox7PTBizszN NHXRbZM1QCCq MlS5SG1UVw>? MUjEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> MVqyNVE1OjFyNh?=
MCF-7 MkjFRZV1d3CqYXf5JGF{e2G7 NHOx[2g{OCCwTR?= MXW0JIg> M1HFR2ROW09? NYrBXm5{UW6mdXPld{BifXSxcHjh[5k> MmfFNlAxOjhzM{S=
U87MG MVrLbY5ie2ViQYPzZZk> NWK4VotIOSEQvF2= M{G3bFYhcA>? NX;iXWo1TE2VTx?= MUXQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>? MWmxPVg1QDRyNB?=
U87MG Mn3YT4lv[XOnIFHzd4F6 M1rTU|Eh|ryP M4HaVFYhcA>? MlWwSG1UVw>? NYXVVpFMWG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44> NIj3c4QyQTh2OESwOC=>
U87MG Mk\LT4lv[XOnIFHzd4F6 MmnNNUDPxE1? NYHUXmRbPiCq M33YNWROW09? MkWzSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NHvFbZEyQTh2OESwOC=>
U87MG MlLWT4lv[XOnIFHzd4F6 MlvQNUDPxE1? MVi2JIg> MliwSG1UVw>? NIjRWW1Fd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25? Mmn1NVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb NEnScVlCfXSxcHjh[5khSXO|YYm= M{LMUlAvOiEQvF2= MYGyOEBp MmjwSG1UVw>? M1e5emlv\HWlZYOgZZV1d3CqYXf5 NET1VHQyQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3 NFfXWHpCfXSxcHjh[5khSXO|YYm= NGq2THAxNjJizszN M2nCXFI1KGh? NWT1dXRiTE2VTx?= NX3LN2Y1UW6mdXPld{BifXSxcHjh[5k> NFrBcWEyQDN7MUm0PS=>
H4 MV7GeY5kfGmxbjDBd5NigQ>? M4TlWVAvOiEQvF2= MWeyOEBp NV3hOGM2TE2VTx?= MXLJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz NIfEW4IyQDB{NEW4OC=>
HeLa NELufWNHfW6ldHnvckBCe3OjeR?= MXWxNFAhdk1? NFLV[Gs{PiCq M3PSZWROW09? MUjJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u NVLkWIc{OTd3NkOzPFU>
HeLa NWnqT4FqTnWwY4Tpc44hSXO|YYm= NHezSG8yODBibl2= NUjiOIZIOzZiaB?= NHLMeIJFVVOR NW\QTIlCUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w MYWxO|U3OzN6NR?=
HeLa MljZSpVv[3Srb36gRZN{[Xl? NWjtfIdZOTByIH7N NUTsXmhLOzZiaB?= NX76dHRqTE2VTx?= NHvLO5NKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> M3GxVFE4PTZ|M{i1
SYF NIjXSo1HfW6ldHnvckBCe3OjeR?= NH\BOWgyODBibl2= MUCyOEBp MlvTSG1UVw>? NFrQO4pKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NIXMfJUyPzV4M{O4OS=>
SYF NUC3TIozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3FfGQyODBibl2= M{DPOVI1KGh? MmDLSG1UVw>? NH7l[YVKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz M1PXSFE4PTZ|M{i1
HEK293T NX3Ed|FESW62aY\pdoFtKEG|c3H5 NVHmSYV5OSCwTR?= NEfZ[|A1KGR? NHnWSpVFVVOR NGPt[lZKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> MXGxO|Q5PTVyMR?=
HEK293T NY\zVoM{SW62aY\pdoFtKEG|c3H5 M4HHclEhdk1? M3;mclQh\A>? MmLpSG1UVw>? Ml\hTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= M{PaUlE4PDh3NUCx
PBMC NXLlW2liTnWwY4Tpc44hSXO|YYm= MmPNNUBvVQ>? Moe2NVQh\A>? MkntSG1UVw>? MmLQVoVlfWOnczDDR3I2KGSnboPpeJk> MWCxO|Q5PTVyMR?=
PBMC M1LK[mZ2dmO2aX;uJGF{e2G7 M3fHRVEhdk1? MXyxOEBl M3zJPWROW09? MVzEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> NEPmbWMyPzR6NUWwNS=>
HEK293 cells M2nidWtqdmG|ZTDBd5NigQ>? NIi4WXU2OCCwTR?= MkTWOFUhdWmw MnPiSG1UVw>? MnnuTY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNUBvVQ>? Mnv0NVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NUn6VHloTnWwY4Tpc44hSXO|YYm= M{P0T|ExOCCwTR?= NYn5PWhNPCCq M3PqUWROW09? NWPIUItDUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? M3r5UlE4OTJ6Mk[y
Human mixed lymphocyte MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m3blUhdk1? NWrGSJRPTE2VTx?= MnyxTWM2OD1zLk[gcm0v M2ewSlE3OTh3OE[1
Lewis rat lymph node cells MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXsOUDPxE1? MnrYSG1UVw>? MoXCTWM2OD1{Lk[g{txO NV75c5BOOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice NVPDTG5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGxNEBvVQ>? NGTMNmM4OiCq MlrzSG1UVw>? M1HBWmlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= MmfDNVAxOjF7NEi=
MRK-nu-1 NF\pd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LnZ2lEPTB;MD64OFUheE1? MX7TRW5ITVJ?
OCUB-M M4TJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi1eFNKSzVyPUWuNlQheE1? NIrGSHpUSU6JRWK=
SF539 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnBTWM2OD1zMT62JJBO NIW2UJFUSU6JRWK=
ES4 NEDPRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi1T|hCUUN3ME2yNU42KHCP NWO4Vop2W0GQR1XS
RL95-2 M1;nNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFyNzDwUS=> MVjTRW5ITVJ?
LC-2-ad NFPLZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTR{MzDwUS=> NVXNOotEW0GQR1XS
Daudi MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\qdZBuUUN3ME20N|QheE1? MYnTRW5ITVJ?
NTERA-S-cl-D1 MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTR2MzDwUS=> MkO5V2FPT0WU
OS-RC-2 NVTVO3k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj6UVM{UUN3ME22OVIheE1? NV\3WW02W0GQR1XS
VA-ES-BJ MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TZRmlEPTB;N{KzJJBO NU\Mbm9CW0GQR1XS
GR-ST NEPEXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\qe5pvUUN3ME24OFYheE1? MX7TRW5ITVJ?
SW872 M2\uZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n3UWlEPTB;OES2JJBO MXnTRW5ITVJ?
NOS-1 NF\ScG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;HdGxKSzVyPUi3NUBxVQ>? NI[yfGxUSU6JRWK=
MC116 NVTxcHZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTl6NTDwUS=> NXjVPJFKW0GQR1XS
NCI-H1355 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDVTWM2OD1zLkCxJI5O NHrPXmpUSU6JRWK=
RPMI-8226 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\NTWM2OD1zLkG5JI5O M4jn[HNCVkeHUh?=
TE-15 NXXEe2xUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjPRo9KSzVyPUGuN|Yhdk1? MVHTRW5ITVJ?
Ramos-2G6-4C10 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnvRZpKSzVyPUGuOFYhdk1? NYDxcpJ1W0GQR1XS
KU812 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUftbIlLUUN3ME2yMlAyKG6P MYfTRW5ITVJ?
EW-1 NVuzXYVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXVTWM2OD1{LkG3JI5O MWTTRW5ITVJ?
KS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwNEWgcm0> MmDZV2FPT0WU
SK-LMS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm0SJFKSzVyPUKuOFkhdk1? NHrWUppUSU6JRWK=
TGBC1TKB MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwNkmgcm0> Mof5V2FPT0WU
TE-6 MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrnU|Y1UUN3ME2yMlc4KG6P MWTTRW5ITVJ?
ETK-1 NHjOTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwOEKgcm0> NWLNNWdyW0GQR1XS
BE-13 M13kPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rIWmlEPTB;Mj65PUBvVQ>? MW\TRW5ITVJ?
A3-KAW NGrvcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT0O|ZKSzVyPUKuPVkhdk1? NFfmUoRUSU6JRWK=
TE-10 M2XDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTufYZ3UUN3ME2zMlMhdk1? NGra[JZUSU6JRWK=
DOHH-2 NHqzZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC4XJpKSzVyPUOuN|Uhdk1? NXrq[nF1W0GQR1XS
ES6 NWfQZWNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWCy[WdiUUN3ME2zMlQ{KG6P MV3TRW5ITVJ?
OPM-2 NY\FSnZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW0boZxUUN3ME20MlE2KG6P MYPTRW5ITVJ?
SH-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDkTWM2OD12LkO0JI5O MmC2V2FPT0WU
NB13 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHNTWM2OD12LkO2JI5O M3LRNHNCVkeHUh?=
HUTU-80 MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rJ[mlEPTB;ND60NkBvVQ>? NWmzclRQW0GQR1XS
CCRF-CEM MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M321NWlEPTB;ND65OEBvVQ>? MlrNV2FPT0WU
TGBC24TKB NEGwPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPTfGhKSzVyPUWuOVEhdk1? MVjTRW5ITVJ?
697 M3;zW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2zTWM2OD14LkK4JI5O MXLTRW5ITVJ?
J-RT3-T3-5 M1jL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTZwNE[gcm0> M4nxb3NCVkeHUh?=
KALS-1 NFfyVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPZTWM2OD14LkW2JI5O M{m5XHNCVkeHUh?=
no-10 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M134NmlEPTB;Nz6yPUBvVQ>? NIfyVpZUSU6JRWK=
SK-NEP-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjxe5RKSzVyPUiuO|khdk1? NFP4[|BUSU6JRWK=
L-540 NXHIc5F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSyTWM2OD1zMD60NkBvVQ>? MmjoV2FPT0WU
JiyoyeP-2003 M1L5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrKSW1oUUN3ME2xNE46PCCwTR?= NXLhUXRKW0GQR1XS
HH M4fkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXnSoJKSzVyPUGxMlM6KG6P M1i4Z3NCVkeHUh?=
SR M3LPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPiTWM2OD1zMT60OUBvVQ>? MVfTRW5ITVJ?
QIMR-WIL M4\NOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u2XGlEPTB;MUGuPFUhdk1? MV;TRW5ITVJ?
A4-Fuk M{PyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF|LkGyJI5O M1vqTHNCVkeHUh?=
CESS Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGyc|hKSzVyPUGzMlE{KG6P M4DGd3NCVkeHUh?=
KE-37 NGXR[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF4LkC3JI5O NYHpdHVoW0GQR1XS
SK-UT-1 M3LaZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LrO2lEPTB;MU[uPFEhdk1? MVzTRW5ITVJ?
SIG-M5 NHjyNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\USlVzUUN3ME2xO{4zPSCwTR?= NFfYTIlUSU6JRWK=
HT M4HEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPoPY1sUUN3ME2xO{43KG6P NVzKW|A2W0GQR1XS
DEL NIHVT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH5TWM2OD1zNz65PUBvVQ>? M2rkNXNCVkeHUh?=
SK-PN-DW NW\3[45ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TnOmlEPTB;MkCuNlMhdk1? MVvTRW5ITVJ?
RPMI-8402 NYexUXpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf4Zo1KSzVyPUKxMlc4KG6P NXjI[Vk4W0GQR1XS
RPMI-6666 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\RZnpKSzVyPUK0MlQzKG6P NVTlOlV3W0GQR1XS
NCI-H720 Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ3LkSxJI5O MonBV2FPT0WU
EW-16 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7yeY9SUUN3ME2yOk45PyCwTR?= NHy5ToRUSU6JRWK=
BL-70 NELNXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXqPGR7UUN3ME2yPE4{QCCwTR?= M{CxTXNCVkeHUh?=
SF126 Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXWOYlKSzVyPUOwMlM5KG6P M3nvfnNCVkeHUh?=
BC-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zTbmlEPTB;M{GuNlYhdk1? NFzTfFZUSU6JRWK=
MHH-PREB-1 Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqycWdKSzVyPUOyMlQ1KG6P MmPoV2FPT0WU
A101D NFnycmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjZWnlKSzVyPUOyMlYzKG6P NXflWVV[W0GQR1XS
NMC-G1 NGPsOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHKVm81UUN3ME2zN{43PyCwTR?= NVrsZ|JiW0GQR1XS
LB1047-RCC MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjOelVKSzVyPUO0MlY6KG6P NEnPcIVUSU6JRWK=
EM-2 MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[0U2VJUUN3ME2zPE42OyCwTR?= MkHqV2FPT0WU
COLO-684 M1zXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXwOG9KSzVyPUO5Mlghdk1? NHrZfHNUSU6JRWK=
Becker M33oOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3JNHN2UUN3ME20NU4xPSCwTR?= MnHmV2FPT0WU
BL-41 NVrUeHhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3voTmlEPTB;NEOuOlYhdk1? M2rqNXNCVkeHUh?=
MDA-MB-134-VI NUTtTYhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPpb3NKSzVyPUS0MlAzKG6P M1X0XnNCVkeHUh?=
L-363 Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLYTWM2OD12ND63N{BvVQ>? NHr1OXBUSU6JRWK=
ECC4 NFjCd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fzSmlEPTB;NESuO|ghdk1? NH\CPJVUSU6JRWK=
A388 NIHuWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXIbGdzUUN3ME20OE45OiCwTR?= M37xTHNCVkeHUh?=
HEL NVyxS5RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33BWmlEPTB;NEmuO|khdk1? NFHzdGlUSU6JRWK=
RKO M3jYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTVyLkK5JI5O MkDRV2FPT0WU
KINGS-1 NUHT[HdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXUTWM2OD13MT61OUBvVQ>? Ml3BV2FPT0WU
EB-3 Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DKcWlEPTB;NUKuOlchdk1? M3[3THNCVkeHUh?=
ARH-77 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTV{Lkigcm0> Ml;FV2FPT0WU
GCIY M3LPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTV|LkS2JI5O M4DxcHNCVkeHUh?=
NCI-H1304 MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTV5LkKyJI5O MnTqV2FPT0WU
KARPAS-299 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu3XXBKSzVyPU[xMlgzKG6P MYDTRW5ITVJ?
IA-LM NEjibphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC1TWM2OD14OD6xN{BvVQ>? MVvTRW5ITVJ?
GI-1 M{G5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTdyLkO5JI5O Mn:3V2FPT0WU
TE-11 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULHTnllUUN3ME23O{4yPyCwTR?= NXLxXnBMW0GQR1XS
LS-411N M1K3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTd5LkW3JI5O M4mwZnNCVkeHUh?=
no-11 M4nDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XHdWlEPTB;OEOuNlQhdk1? MlnEV2FPT0WU
MV-4-11 M{PncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\hXpI6UUN3ME24N{44OyCwTR?= M2j5R3NCVkeHUh?=
BV-173 MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTh|Lkm3JI5O M3z5RXNCVkeHUh?=
CMK M1qwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn0OnhKSzVyPUi0MlE3KG6P MYDTRW5ITVJ?
LC4-1 NFL5bG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPEWlJZUUN3ME24Ok44OiCwTR?= MnTmV2FPT0WU
COR-L279 NVr2WZZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jJb2lEPTB;OEeuNlUhdk1? NFPCR3NUSU6JRWK=
NCI-H209 M4jzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTh5LkSxJI5O NWftOo44W0GQR1XS
Raji M1q2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\MWWlEPTB;OEmuO|Ihdk1? NEnPOFJUSU6JRWK=
LB996-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\4OmlEPTB;OUOuOFMhdk1? M{XTVnNCVkeHUh?=
NCI-H526 M1HxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXCTWM2OD17Mz61PUBvVQ>? M2nkXnNCVkeHUh?=
KGN NGrz[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTl4LkK5JI5O M{\rVnNCVkeHUh?=
MOLT-4 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jrfGlEPTB;OU[uO|khdk1? NIjNXoNUSU6JRWK=
PF-382 NHnO[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXYXlJyUUN3ME25Ok44QSCwTR?= NELSfZZUSU6JRWK=
BC-3 NH[wb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzMeZZnUUN3ME25PU4yQCCwTR?= MnLKV2FPT0WU
KARPAS-422 M2T5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfxN5BFUUN3ME2xNFIvODlibl2= MmrEV2FPT0WU
SBC-1 Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LMWmlEPTB;MUC3Mlc2KG6P MojtV2FPT0WU
LC-1F M{PuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmxZ2dKSzVyPUGwPE4xPSCwTR?= MknwV2FPT0WU
GB-1 MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXTXXkxUUN3ME2xNFkvODJibl2= NELjWoRUSU6JRWK=
SNB75 NXvPXVJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWGxNFN[UUN3ME2xNVkvPjlibl2= MU\TRW5ITVJ?
BB65-RCC M2HCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXBTWM2OD1zMUmuPVMhdk1? MUnTRW5ITVJ?
NCI-N87 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPvUY9KSzVyPUGyNU46QCCwTR?= M3XMcHNCVkeHUh?=
IST-MEL1 NEWySGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7jNIlDUUN3ME2xNlIvOzhibl2= M1HMTXNCVkeHUh?=
HOP-62 NXHETY1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PRVGlEPTB;MUK2Mlg6KG6P Mn;jV2FPT0WU
ACN M2mwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj6UIZKSzVyPUG0Ok44PSCwTR?= MWPTRW5ITVJ?
DMS-114 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;2VpZKSzVyPUG1NE43PyCwTR?= NWnBbIY4W0GQR1XS
MLMA M{nmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnUTWM2OD1zNUmuPFghdk1? MnrpV2FPT0WU
HT-144 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrxdWtKSzVyPUG2OU41OyCwTR?= M3K4T3NCVkeHUh?=
C2BBe1 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\iZoVKSzVyPUG2O{44PiCwTR?= NVTpdHJjW0GQR1XS
L-428 MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\YdGlEPTB;MUe3Mlchdk1? MVvTRW5ITVJ?
DU-4475 M3\kVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofmTWM2OD1zOEeuOlghdk1? NF:5dWRUSU6JRWK=
CP67-MEL NYC1NZBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLk[mszUUN3ME2xPVkvOzhibl2= NGPJRnRUSU6JRWK=
MEG-01 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHBenJKSzVyPUKwNU46PiCwTR?= MXLTRW5ITVJ?
IST-SL2 M4LCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TURWlEPTB;MkC4MlY{KG6P MmP6V2FPT0WU
ES8 MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJ{NT65OEBvVQ>? NFHa[JVUSU6JRWK=
COLO-800 M3vGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnzbVY1UUN3ME2yN|UvOjhibl2= MX7TRW5ITVJ?
MFH-ino M{fIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz4U202UUN3ME2yN|UvQDRibl2= NF3CVGVUSU6JRWK=
OVCAR-4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HXeWlEPTB;MkO3MlI1KG6P NVnOZ|JqW0GQR1XS
PSN1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i0T2lEPTB;MkSyMlcyKG6P NHHnNoFUSU6JRWK=
EW-12 Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfwN49yUUN3ME2yOFMvOSCwTR?= MUXTRW5ITVJ?
HCC1599 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW2bXVKSzVyPUK2NU41PyCwTR?= NIjLR4tUSU6JRWK=
SJSA-1 NH63epFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGyb414UUN3ME2yO|EvPDZibl2= MULTRW5ITVJ?
ST486 M4TsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzYcpBNUUN3ME2yPVYvOTRibl2= NV3mU3h{W0GQR1XS
NOMO-1 NHvmPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNyMD6yNUBvVQ>? Mmf1V2FPT0WU
MN-60 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXNS3EzUUN3ME2zNFUvOzJibl2= MYHTRW5ITVJ?
HCC1187 M{XCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTNyNz6yOUBvVQ>? NF;w[HVUSU6JRWK=
SW982 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK3TWM2OD1|MUSuO|Uhdk1? M4P6[XNCVkeHUh?=
LB647-SCLC NIXIemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHsTWM2OD1|MkiuO|Ehdk1? MWLTRW5ITVJ?
HC-1 M3;X[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;MTWM2OD1|M{WuOUBvVQ>? MmO5V2FPT0WU
EHEB M{\mSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTN|Nz61NkBvVQ>? MoS3V2FPT0WU
TUR M{nxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvTW2NKSzVyPUO2N{46PSCwTR?= M2m3bHNCVkeHUh?=
LU-139 MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHsXZFKSzVyPUO3PE4xOiCwTR?= MVXTRW5ITVJ?
NB1 M4TvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrlbIR[UUN3ME2zPFQvPDVibl2= NEHZblFUSU6JRWK=
BB30-HNC NYjnOZlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PGTWlEPTB;M{i4MlMzKG6P NYj6SJBLW0GQR1XS
HAL-01 MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;LTWM2OD1|OEmuNlYhdk1? MXTTRW5ITVJ?
K5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTRzMT6zO{BvVQ>? NIjCfI1USU6JRWK=
MZ2-MEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7jNIdiUUN3ME20NVMvPjRibl2= NFnLUFJUSU6JRWK=
RXF393 NFHkW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHhe41KSzVyPUSxOk41PSCwTR?= MoD0V2FPT0WU
NCI-H1648 MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTRzNz61N{BvVQ>? MUPTRW5ITVJ?
TE-12 NIj6bmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknBTWM2OD12M{SuNlYhdk1? NYP4fplqW0GQR1XS
EoL-1- NGrNOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLDeIw{UUN3ME20N|cvQThibl2= MVTTRW5ITVJ?
JAR Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M125TmlEPTB;NEO4MlYzKG6P NX3vcG54W0GQR1XS
DSH1 M3;vUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rIOWlEPTB;NEW4MlkyKG6P Mk\WV2FPT0WU
NCI-H187 M1jUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjWVJlKSzVyPUS2Nk45OSCwTR?= NHf1TGlUSU6JRWK=
HCE-4 NV3YWVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\hTWM2OD12N{euOlYhdk1? NGHMb3dUSU6JRWK=
8-MG-BA NEDy[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXXTpQ1UUN3ME21PFEvPTJibl2= NEnldVhUSU6JRWK=
KLE M4HwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTV6NT6yJI5O M{PENnNCVkeHUh?=
KNS-42 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTV6Nj64NUBvVQ>? MnqzV2FPT0WU
MSTO-211H M13CZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrCNm9RUUN3ME22NFkvPzRibl2= MVrTRW5ITVJ?
GDM-1 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTZzND6wPUBvVQ>? NHnPNFBUSU6JRWK=
TE-1 NV7QbHdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\QTmhKSzVyPU[0Ok4yOiCwTR?= NWPWTZJoW0GQR1XS
BT-474 NHntUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPsSolKSzVyPU[0O{4xPiCwTR?= NFK0S|FUSU6JRWK=
KARPAS-45 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vnN2lEPTB;NkS3MlYhdk1? MVLTRW5ITVJ?
MOLT-16 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[2XWlEPTB;NkS3Mlk{KG6P MkfWV2FPT0WU
KURAMOCHI MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfmRWw6UUN3ME22OVcvPTFibl2= NGnhNpVUSU6JRWK=
K-562 NWC5c5hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7rTWM2OD14NkmuOVEhdk1? M37iVnNCVkeHUh?=
EKVX MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjUbINKSzVyPU[3Nk44OSCwTR?= MUHTRW5ITVJ?
GAK M1WxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPoTWM2OD14N{WuN{BvVQ>? MVXTRW5ITVJ?
NCI-SNU-5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTZ7MD6wNUBvVQ>? NYG0SJVHW0GQR1XS
NCI-H2126 NIHrUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPPOXJIUUN3ME23NlYvQDdibl2= NVT0c|NPW0GQR1XS
CTV-1 NXq0d3BPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTd2ND65JI5O MYfTRW5ITVJ?
SW962 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3YTWM2OD15NEiuOFQhdk1? NXHQfllrW0GQR1XS
MONO-MAC-6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H1PGlEPTB;N{W2Mlk{KG6P MVnTRW5ITVJ?
NCI-H748 M3XLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjOTWM2OD15NUiuPVkhdk1? NWDi[JV6W0GQR1XS
NCI-H524 NEHSUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j4VGlEPTB;N{iwMlc{KG6P NH7zO5ZUSU6JRWK=
LS-123 NH\HeXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7aTWM2OD15OUWuOlkhdk1? NEL1SpNUSU6JRWK=
NB7 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fx[mlEPTB;OEG0MlE1KG6P M1L0UXNCVkeHUh?=
LS-1034 NX\LS2dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7tTWM2OD16MkiuPVghdk1? NHmxUWdUSU6JRWK=
TE-5 NIPzc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HVWmlEPTB;OEizMlU3KG6P NXe1dY5mW0GQR1XS
A704 NFewNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTh7OT6xOUBvVQ>? MlfHV2FPT0WU
TK10 NXfhSoRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3iTYtKSzVyPUmxOk4xOyCwTR?= M33SOHNCVkeHUh?=
NCI-H345 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfNTWM2OD17NEOuNlIhdk1? NUn5RXc4W0GQR1XS
CGTH-W-1 NGflSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PMRmlEPTB;OUS4MlE{KG6P NX7NN5JGW0GQR1XS
NCI-H510A MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7iTWM2OD17OEWuNVIhdk1? NF;ENFVUSU6JRWK=
NCI-H1963 NH;CRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwMEOyPVIh|ryP M2TPTXNCVkeHUh?=
SCC-3 NFHUO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Xp[2lEPTB;MT6wN|QyPCEQvF2= NEHHSmxUSU6JRWK=
EW-11 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwMEi3OFMh|ryP MYPTRW5ITVJ?
CPC-N NYHhZWNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrKbXlKSzVyPUGuNFg5KM7:TR?= MVvTRW5ITVJ?
NCI-H1417 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDETWM2OD1zLkGyNlYh|ryP MUPTRW5ITVJ?
DG-75 NWntSHA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFwMU[yPFUh|ryP M3rNNHNCVkeHUh?=
HD-MY-Z MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\yT2VKSzVyPUGuNVY1OTZizszN M2j0fHNCVkeHUh?=
ATN-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfzTWM2OD1zLkK2NlA6KM7:TR?= Ml7CV2FPT0WU
KM-H2 NGPteotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULQNZlJUUN3ME2xMlI3PDB6IN88US=> NXqx[ppoW0GQR1XS
NCI-H2081 M3m5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PMcmlEPTB;MT6yOlY{PyEQvF2= MlHvV2FPT0WU
HL-60 NXXONoQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUiwOpIyUUN3ME2xMlI3QTV7IN88US=> NIDo[o1USU6JRWK=
DB MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H5[mlEPTB;MT6yO|I1OiEQvF2= M1XkSXNCVkeHUh?=
NCI-H1522 M4TOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwMki4PFch|ryP NEPMUZVUSU6JRWK=
AM-38 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX6cFBDUUN3ME2xMlMxPzJizszN NXzCVVdpW0GQR1XS
NCI-H446 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwM{KxNlEh|ryP NI\FWYpUSU6JRWK=
SU-DHL-1 NVX0S5c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwM{K4NFEh|ryP M1XSWHNCVkeHUh?=
NH-12 Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLiZZlKSzVyPUGuN|Y{PzRizszN NVnCNlJLW0GQR1XS
DMS-79 NUPRUmF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwM{[4OlYh|ryP NILPUphUSU6JRWK=
NCI-H716 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3vPY5KSzVyPUGuN|g6QDZizszN M1GzR3NCVkeHUh?=
ML-2 NGXxbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XFfGlEPTB;MT60NVUzQSEQvF2= NWPGeG93W0GQR1XS
NB10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf2eHlKSzVyPUGuOFY3OzJizszN MYLTRW5ITVJ?
ONS-76 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XtPWlEPTB;MT61N|U3QSEQvF2= NE\CS3JUSU6JRWK=
LOUCY NUXFT5lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jJV2lEPTB;MT61OFY2PyEQvF2= MoiyV2FPT0WU
SCLC-21H M2LmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\Rc3pDUUN3ME2xMlU5PTh{IN88US=> MWLTRW5ITVJ?
TGW MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrMOmpKSzVyPUGuOlM6PzVizszN M1TjPXNCVkeHUh?=
LXF-289 M{HtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnZcpljUUN3ME2xMlc{OjZ6IN88US=> NIjSOm9USU6JRWK=
BB49-HNC NG\WPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTFwN{O1PFYh|ryP NWqye3FpW0GQR1XS
NCI-H747 NWKzUpc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWxUZJKSzVyPUGuO|U{PDZizszN M1nX[3NCVkeHUh?=
LU-165 NIfTe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki0TWM2OD1zLki0PVg3KM7:TR?= NUTSNWp[W0GQR1XS
OMC-1 NHj6UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TCUGlEPTB;MT65OVA3PiEQvF2= NXnY[m5iW0GQR1XS
RCC10RGB NFfye4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnLe4E5UUN3ME2xMlk2QDF5IN88US=> MmHMV2FPT0WU
SW684 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zzSGlEPTB;MT65OlA6QSEQvF2= MkPnV2FPT0WU
TE-8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjrfJNKSzVyPUKuNFU2PTlizszN NVfXV4hoW0GQR1XS
SK-N-DZ MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3zXlZXUUN3ME2yMlE{Ojd2IN88US=> NGrjS5ZUSU6JRWK=
EVSA-T NFXIZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PyR2lEPTB;Mj6xO|MyPSEQvF2= MWrTRW5ITVJ?
KASUMI-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn3R3ZsUUN3ME2yMlE5QDF3IN88US=> Mn\4V2FPT0WU
NKM-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrLTWM2OD1{LkK1OFczKM7:TR?= Mk\ZV2FPT0WU
CAL-148 NGj0[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJwM{O2NVQh|ryP NXPFfWhjW0GQR1XS
NCI-H64 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS4TWM2OD1{LkO0NlMzKM7:TR?= MkjXV2FPT0WU
KNS-81-FD MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJwM{[2NkDPxE1? NYjwd2FPW0GQR1XS
KM12 Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJwNEC4N|kh|ryP NHu4W3RUSU6JRWK=
SW954 NVLNSnpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwNEe3O|kh|ryP NEH2RohUSU6JRWK=
NCI-H1395 NFz6VVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe5N2VXUUN3ME2yMlUzPjR3IN88US=> NX7BcXd2W0GQR1XS
DJM-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu1WJhKSzVyPUKuOlA3OyEQvF2= MontV2FPT0WU
COLO-668 M1LQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;yeIRKSzVyPUKuPFI3QTVizszN NVTBNXg4W0GQR1XS
NCI-H1436 NH3yNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi2UplKSzVyPUKuPFU3OTVizszN NFzWVWNUSU6JRWK=
LB2241-RCC NGrhe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDGRYlKSzVyPUKuPFY5OzlizszN MlS3V2FPT0WU
GT3TKB MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL3TWM2OD1{Lki5NFU2KM7:TR?= M2riRXNCVkeHUh?=
COLO-824 M13KdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jKe2lEPTB;Mj64PVc3QCEQvF2= M1\6UHNCVkeHUh?=
ES1 MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJwOEm4O|kh|ryP NFe1cplUSU6JRWK=
LB771-HNC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH3TWM2OD1{LkmwPVQ3KM7:TR?= MV7TRW5ITVJ?
GI-ME-N M1vnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnFXpJKSzVyPUOuNFA6ODRizszN NW\NfZFGW0GQR1XS
NALM-6 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzhTWM2OD1|LkCwPVM{KM7:TR?= MlvOV2FPT0WU
LU-134-A MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXrbI1KSzVyPUOuNFU1OjVizszN MWLTRW5ITVJ?
DMS-153 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13XTmlEPTB;Mz6wOVgzPCEQvF2= NVThR41NW0GQR1XS
MZ1-PC NHroZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\5V5dNUUN3ME2zMlA6ODd6IN88US=> M1XRcnNCVkeHUh?=
NCI-H1155 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K1O2lEPTB;Mz6xNVYyKM7:TR?= Ml7iV2FPT0WU
CAS-1 NF6xR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuzVo9KSzVyPUOuNVM4ODdizszN MYHTRW5ITVJ?
D-502MG NHvrS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfITWM2OD1|LkG0N|kh|ryP M13OdXNCVkeHUh?=
NCI-H2141 NWGyNGg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjQTWM2OD1|LkG3OFUzKM7:TR?= MknOV2FPT0WU
NB6 NXjJ[WJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNwMUiyOVkh|ryP MknQV2FPT0WU
NCCIT M4\oSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTNwMkG4NFkh|ryP M4LHUnNCVkeHUh?=
NB69 NGK0XXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnGTWM2OD1|LkOxPFkyKM7:TR?= MVXTRW5ITVJ?
JVM-2 NIrETmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT0TWM2OD1|LkO2OFM{KM7:TR?= MYXTRW5ITVJ?
K052 Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3nT5FKSzVyPUOuN|c6PjhizszN NX7yW213W0GQR1XS
HCC2157 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTNwNUOyNlgh|ryP Ml71V2FPT0WU
KMOE-2 NXHLT5FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNwNUSyOFIh|ryP NWfMdXFRW0GQR1XS
SF268 NV3zV2dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K4[WlEPTB;Mz63NVU2PCEQvF2= M1noSXNCVkeHUh?=
CHP-126 NYnW[Hk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TOTWlEPTB;Mz63OlQ2QCEQvF2= M1jFeHNCVkeHUh?=
CP66-MEL Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO0c5FKSzVyPUOuO|kxQTRizszN NVP5PGVrW0GQR1XS
NCI-H69 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTRwMEG5N|Yh|ryP NUe3eWk1W0GQR1XS
A253 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H5SGlEPTB;ND6wNlExOSEQvF2= NUfoWnFmW0GQR1XS
NB14 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH5TWM2OD12LkGwOFc6KM7:TR?= NFTyUVBUSU6JRWK=
NCI-H1694 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTRwMUOxNVIh|ryP MoXZV2FPT0WU
NCI-H2196 NFHaN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7LTWM2OD12LkG3NVY6KM7:TR?= MoPnV2FPT0WU
TE-9 NULMZ4xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7NTXFlUUN3ME20MlE4PTh{IN88US=> NX3Mb3JuW0GQR1XS
D-283MED M1zxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfjVWhKSzVyPUSuNVg5PCEQvF2= M1S4OHNCVkeHUh?=
OCI-AML2 NW\KcW9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\vTWM2OD12LkG5OFg6KM7:TR?= NUfte5d6W0GQR1XS
D-263MG NHy2XHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPGTG9KSzVyPUSuNlI6PjFizszN NE\Md5NUSU6JRWK=
MPP-89 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;UN2FKSzVyPUSuNlc{ODRizszN NVvRb3pTW0GQR1XS
LAMA-84 MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTRwM{C0NlEh|ryP NFzIdJNUSU6JRWK=
LB373-MEL-D NUfIPGQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjHVWpKSzVyPUSuN|Y4QDlizszN NX3BbmhHW0GQR1XS
UACC-257 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTRwM{m1N|Qh|ryP M4PiWHNCVkeHUh?=
MC-CAR NGnTXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrQcoJKSzVyPUSuOFM6QSEQvF2= MlfvV2FPT0WU
COLO-320-HSR NHyzS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTRwNES0Nlch|ryP M37GVXNCVkeHUh?=
P30-OHK MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTRwNk[1PFEh|ryP NVizeYtwW0GQR1XS
UACC-812 NWLZO2RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPSZoprUUN3ME20MlY6OTZzIN88US=> NFLCTGhUSU6JRWK=
CTB-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTRwN{G1OVUh|ryP NWHIU3BqW0GQR1XS
ALL-PO M{niVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\lTWM2OD12Lki0NFc4KM7:TR?= M1jzbXNCVkeHUh?=
SK-MEL-2 Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\QWm1KSzVyPUSuPFY6PTVizszN MUDTRW5ITVJ?
TC-YIK MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTHPYVKSzVyPUSuPVc6PDJizszN M4exXHNCVkeHUh?=
NCI-H1882 M1jJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL3TWM2OD13LkCyNFAyKM7:TR?= M2f3RnNCVkeHUh?=
MHH-CALL-2 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TYVmlEPTB;NT6wOVA1OiEQvF2= M2DYOHNCVkeHUh?=
U-87-MG MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXzWWxkUUN3ME21MlA6PDZ4IN88US=> NUPvSlZKW0GQR1XS
NCI-H1092 M3zxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\yTWM2OD13LkK2OVU2KM7:TR?= M2\Se3NCVkeHUh?=
TE-441-T MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DDVmlEPTB;NT6yO|gzKM7:TR?= MorUV2FPT0WU
SK-MEL-1 M2nyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[0WWtKSzVyPUWuNlkxPDRizszN Ml;VV2FPT0WU
EW-22 NEnFPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHETWM2OD13LkK5OFY3KM7:TR?= NX60RXBnW0GQR1XS
MZ7-mel M3y0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW3TWM2OD13LkSwOlkyKM7:TR?= MX3TRW5ITVJ?
LP-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjQUox5UUN3ME21MlQyOjlzIN88US=> MUPTRW5ITVJ?
NCI-SNU-16 M3TRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGntdohKSzVyPUWuOlQxPzRizszN MnqyV2FPT0WU
LU-65 M1TuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXDTWM2OD13Lke2N|c{KM7:TR?= MlS4V2FPT0WU
CW-2 M{n4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXYTWM2OD13Lki1PVU6KM7:TR?= MmDkV2FPT0WU
WSU-NHL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K0OmlEPTB;NT65OVE4PCEQvF2= M336PXNCVkeHUh?=
IST-MES1 NWm2ZlNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTvcJlVUUN3ME21Mlk2PDR|IN88US=> NHO1SWhUSU6JRWK=
U-266 M1G2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHlTWM2OD13Lkm4NlAzKM7:TR?= M{G3[HNCVkeHUh?=
TALL-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vZc2lEPTB;Nj6xOFY5QCEQvF2= NUDUT2dzW0GQR1XS
Calu-6 M2[xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DMZWlEPTB;Nj6xOVMyPiEQvF2= MkLMV2FPT0WU
MMAC-SF M1fjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ETWM2OD14LkG4OVU3KM7:TR?= M37FSHNCVkeHUh?=
NCI-H82 MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTZwMkC0PFkh|ryP MV;TRW5ITVJ?
RS4-11 MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTZwMkW4PVch|ryP M1LVTXNCVkeHUh?=
SNU-C2B NIjHcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTZwNEC5Olkh|ryP MYDTRW5ITVJ?
BOKU MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\MTWM2OD14LkS3OVk4KM7:TR?= MoHQV2FPT0WU
C8166 M{GwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;LNXl7UUN3ME22MlU2QTF{IN88US=> NInsWXVUSU6JRWK=
D-247MG MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;yVGlEPTB;Nz6wOFM1PyEQvF2= M1K1[nNCVkeHUh?=
EW-18 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTdwMEeyPVIh|ryP MoLHV2FPT0WU
KG-1 NVjV[4ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHiWm5KSzVyPUeuOlI4OzhizszN MUjTRW5ITVJ?
REH Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHixPIxKSzVyPUeuOlgyODlizszN MXTTRW5ITVJ?
U-698-M MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zhZ2lEPTB;Nz64OFMyPSEQvF2= MlruV2FPT0WU
KP-N-RT-BM-1 NVvQZlFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTdwOUOwNlkh|ryP NFyzem1USU6JRWK=
MS-1 MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TsR2lEPTB;Nz65OlA1OSEQvF2= MmXiV2FPT0WU
SNU-C1 NHfodolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljhTWM2OD15Lkm4NVkzKM7:TR?= NHjROpVUSU6JRWK=
SK-MM-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLYWIFKSzVyPUiuNlYxPjVizszN NHnDc4RUSU6JRWK=
LAN-6 NX\tdJplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRThwM{CwNFEh|ryP NHHidlhUSU6JRWK=
NEC8 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRThwM{C2PVEh|ryP MkfyV2FPT0WU
NCI-H1770 Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRThwM{iwNFIh|ryP NXvVXY5tW0GQR1XS
D-336MG NWfmRnhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLETWM2OD16LkSwNVE3KM7:TR?= M4PRcXNCVkeHUh?=
COLO-829 M{nhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRThwNEi4O|kh|ryP NXPTVoRnW0GQR1XS
LS-513 NF;2N|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fuPWlEPTB;OD61PVU6QSEQvF2= MU\TRW5ITVJ?
YT MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;1fGlEPTB;OD62NlQzPyEQvF2= NYLRRZkxW0GQR1XS
EW-24 M4S5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPzTWM2OD16Lke2OVQh|ryP MXTTRW5ITVJ?
IST-SL1 NHTTUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;BRXhLUUN3ME24Mlg3PTR|IN88US=> M3TE[XNCVkeHUh?=
CA46 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXlfm9sUUN3ME24Mlk2ODl6IN88US=> NHuyVGNUSU6JRWK=
NCI-H1838 M{nTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRThwOUi2NFIh|ryP NWLpZXVTW0GQR1XS
NCI-H719 NXG1UoQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHuTWM2OD17LkK1Nlc6KM7:TR?= M2\VfHNCVkeHUh?=
HCE-T MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvCTWM2OD17LkOwPFUyKM7:TR?= M1fIN3NCVkeHUh?=
A498 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTlwM{[xNlQh|ryP NGHxRlJUSU6JRWK=
LB831-BLC NGfvOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjK[5hKSzVyPUmuO|Y2OjFizszN MYLTRW5ITVJ?
SKM-1 M13QSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTlwOEW5OlMh|ryP NEHKbFJUSU6JRWK=
THP-1 M1O4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkToTWM2OD17Lkm2PVE5KM7:TR?= NFLmdIFUSU6JRWK=
SHP-77 M2G1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfPdFZKSzVyPUGwMlQxPyEQvF2= M3jTb3NCVkeHUh?=
EW-3 NYDscXd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjS[5lsUUN3ME2xNE43Ojh7IN88US=> NVrQPWp2W0GQR1XS
KY821 NEmxWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFyLke2N{DPxE1? NWPwSW1NW0GQR1XS
NCI-SNU-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFzLkCyNVch|ryP NX3nfXhHW0GQR1XS
HCC2218 Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFzLkO5PFYh|ryP M2fzTnNCVkeHUh?=
IM-9 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFzLkWxNFYh|ryP MnrOV2FPT0WU
NCI-H889 NXj0V|B4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPNNWNKSzVyPUGxMlU{OTNizszN M1XYfHNCVkeHUh?=
HDLM-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPjTWM2OD1zMj60NVU6KM7:TR?= MYnTRW5ITVJ?
LB2518-MEL MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LBbmlEPTB;MUKuOlgyPSEQvF2= NIjEZ2xUSU6JRWK=
NCI-H23 NETQW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF|LkK0NlUh|ryP NWDZcJcyW0GQR1XS
NB17 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvCUYxKSzVyPUGzMlQ2PzlizszN MkS1V2FPT0WU
NCI-H322M NYW3[pZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\FWHVLUUN3ME2xOE41ODZ6IN88US=> NFe4dIpUSU6JRWK=
SUP-T1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHCTWM2OD1zND60NVMh|ryP MWPTRW5ITVJ?
ES3 NI\ZV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW1U3FKSzVyPUG1MlA4ODNizszN M{DyR3NCVkeHUh?=
ES5 NUfiOJBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF3LkC3PFch|ryP MUXTRW5ITVJ?
NCI-H1650 NF7sbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF3LkS5O|kh|ryP Mmn3V2FPT0WU
NCI-H226 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX2S3JKSzVyPUG1Mlg4PjhizszN NIXVOnlUSU6JRWK=
COR-L88 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX3XoJoUUN3ME2xOk4{OTRizszN M4XhdXNCVkeHUh?=
SCC-15 MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInoR2JKSzVyPUG2MlM5PjlizszN MkLOV2FPT0WU
GOTO MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkftTWM2OD1zNj60O|k{KM7:TR?= NF;YV2pUSU6JRWK=
SIMA NWPn[mlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjLZlJnUUN3ME2xOk41QDB{IN88US=> NUjBW5VTW0GQR1XS
NCI-H1299 NVzWbY9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF5LkG1PVEh|ryP M{PuWHNCVkeHUh?=
NCI-H1581 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF5LkSyNVkh|ryP MUPTRW5ITVJ?
MHH-NB-11 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGwTWM2OD1zNz65Olg{KM7:TR?= MXfTRW5ITVJ?
MFM-223 M4DPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPQcpFYUUN3ME2xPE4xPTN6IN88US=> NV\nV41QW0GQR1XS
ES7 NXS2T2NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33SVGlEPTB;MUiuOVQ{OSEQvF2= MkfQV2FPT0WU
JVM-3 M4X6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrOVo1xUUN3ME2xPE44OTdizszN M1H2PXNCVkeHUh?=
RL M4fKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3QTWM2OD1{MD6zPFgh|ryP MUTTRW5ITVJ?
EC-GI-10 NIfJSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEeyZXhKSzVyPUKxMlIxPDFizszN NVHYeXhXW0GQR1XS
LNCaP-Clone-FGC M4i2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjhTWM2OD1{MT62O|Y5KM7:TR?= MVjTRW5ITVJ?
IMR-5 NG\WXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;vS25KSzVyPUKxMlg1QTRizszN Mo\pV2FPT0WU
KP-N-YS MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfqTWM2OD1{MT64O|Uh|ryP NUfPSZI1W0GQR1XS
Mo-T M3;ES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjwXG5oUUN3ME2yNk4zOTh3IN88US=> NHTPSYZUSU6JRWK=
NCI-H128 NWPxfGJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfKTWM2OD1{Mz61PFU{KM7:TR?= MnrhV2FPT0WU
RH-1 M13F[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ|Lke4OlYh|ryP NUnCOJJtW0GQR1XS
NCI-H2171 NH3XcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\hUXdDUUN3ME2yOE4zPDh3IN88US=> NIHObJBUSU6JRWK=
RPMI-8866 NVLhd|l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\WZ|lbUUN3ME2yOk44PDJizszN MljPV2FPT0WU
SK-N-FI MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\GO2NkUUN3ME2yO{4{QDFzIN88US=> M3HPbnNCVkeHUh?=
LOXIMVI M33GOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\EOFVHUUN3ME2yO{45ODVzIN88US=> M1zNRnNCVkeHUh?=
P31-FUJ NXHQbo5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHFTWM2OD1|MT61N|c1KM7:TR?= M1y2SXNCVkeHUh?=
KMS-12-PE NWrhRVNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4mweWlEPTB;NEmuOVMxOiEQvF2= M1XidHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID